EMA Urges Makers of Urokinase Drugs to Estimate Pathogen Contamination Probability

Drug Industry Daily
A A
While advances in technology have improved the purity profile of urokinase-based drugs, EU regulators are urging makers of these drugs to estimate the risk that an individual dose of a product might be contaminated with pathogens.

To View This Article:

Login

Subscribe To Drug Industry Daily